<DOC>
	<DOCNO>NCT02312375</DOCNO>
	<brief_summary>This study design evaluate effect ARB improve insulin secretion patient type 2 diabetes . The investigator also aim evaluate potential synergism ARB DPP4 inhibitor improve insulin secretion urinary albumin secretion diabetic patient .</brief_summary>
	<brief_title>Effects Fimasartan Insulin Secretion Type 2 Diabetic Patients</brief_title>
	<detailed_description>Angiotensin II report insulin secretion beta cell . Angiotensin II indirectly improve insulin secretion beta cell via vasoconstriction reduce islet blood flow . Chronic exposure high glucose high fat increase expression AT1R ( angiotensin type 1 receptor ) , lead reactive oxidative stress , inflammation , apoptosis beta cell , finally decrease insulin formation secretion . Some study show beneficial effect block AT1R insulin secretion beta cell proliferation animal model use angiotensin receptor blocker ( ARB ) . Furthermore , 26 week valsartan treatment improve insulin secretion human impair glucose regulation .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Aged 20~80 year Type 2 diabetic patient diagnose 6 month ago HbA1c ≤8.5 % screen No change OAD within 3 month screen SBP &lt; 140 mmHg DBP &lt; 90 mmHg antihypertensive drug screen SBP ≥140 mmHg DBP ≥80 mmHg without antihypertensive drug screen Type 1 diabetic patient active insulin treatment screen Treatment ARB ACEi within 1 month prior screen Uncontrolled hypertension SBP &gt; 170 mmHg DBP &gt; 100 mmHg Pregnancy lactation Elevated liver enzyme ( AST ALT &gt; 3 time UNL ) elevate serum Cr ( ≥1.5 mg/dL men 1.4 mg/dL woman )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>